Moomoo AI 已提取核心信息
On December 31, 2023, a Schedule 13G/A filing was made with the United States Securities and Exchange Commission by PFM Health Sciences, LP, PFM Health Sciences GP, LLC, Partner Asset Management, LLC, and Brian D. Grossman, collectively referred to as the Reporting Persons, regarding their ownership in bluebird bio, Inc. The filing indicates that these entities and individuals collectively hold 2,042,651 shares of bluebird bio's common stock, which represents approximately 1.9% of the company's outstanding common stock as of November 3, 2023. The Reporting Persons have shared voting and dispositive power over these shares. The filing was certified as true and correct by Darren Mooney, authorized signatory, on February 14, 2024. The address for the principal business office of the Reporting Persons is in San Francisco, California. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of bluebird bio, Inc.
On December 31, 2023, a Schedule 13G/A filing was made with the United States Securities and Exchange Commission by PFM Health Sciences, LP, PFM Health Sciences GP, LLC, Partner Asset Management, LLC, and Brian D. Grossman, collectively referred to as the Reporting Persons, regarding their ownership in bluebird bio, Inc. The filing indicates that these entities and individuals collectively hold 2,042,651 shares of bluebird bio's common stock, which represents approximately 1.9% of the company's outstanding common stock as of November 3, 2023. The Reporting Persons have shared voting and dispositive power over these shares. The filing was certified as true and correct by Darren Mooney, authorized signatory, on February 14, 2024. The address for the principal business office of the Reporting Persons is in San Francisco, California. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of bluebird bio, Inc.
2023年12月31日，PFM Health Sciences, LP、PFM Health Sciences GP, LLC、Partner Asset Management, LLC和Brian D. Grossman（统称为 “申报人”）向美国证券交易委员会提交了附表13G/A的文件。该文件显示，这些实体和个人共持有蓝鸟生物普通股的2,042,651股，这意味着截至2023年11月3日，该公司已发行普通股的约1.9％。申报人对这些股票拥有共同的投票权和处置权。该文件于2024年2月14日由授权签署人达伦·穆尼认证为真实和正确。申报人主要业务办公室的地址在加利福尼亚州的旧金山。该文件称，收购这些股票不是为了改变或影响蓝鸟生物公司的控制权。
2023年12月31日，PFM Health Sciences, LP、PFM Health Sciences GP, LLC、Partner Asset Management, LLC和Brian D. Grossman（统称为 “申报人”）向美国证券交易委员会提交了附表13G/A的文件。该文件显示，这些实体和个人共持有蓝鸟生物普通股的2,042,651股，这意味着截至2023年11月3日，该公司已发行普通股的约1.9％。申报人对这些股票拥有共同的投票权和处置权。该文件于2024年2月14日由授权签署人达伦·穆尼认证为真实和正确。申报人主要业务办公室的地址在加利福尼亚州的旧金山。该文件称，收购这些股票不是为了改变或影响蓝鸟生物公司的控制权。
有用
没用